New HIV vaccine strategy aims to prime and boost immune defenses
NCT ID NCT07675629
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests a two-part HIV vaccine in healthy adults who do not have HIV. The vaccine uses a DNA 'prime' followed by a protein 'boost' to train the immune system against multiple HIV strains. Researchers are checking if the vaccine is safe and whether it triggers a strong immune response. The trial includes 126 volunteers and compares two different adjuvants (substances that boost the immune reaction).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDPHV HIV-1 vaccine (DNA prime and gp120 protein boost with adjuvant)
What this could lead to
If successful, this could pave the way for an effective HIV vaccine, potentially preventing infection.
What could go wrong
This is an early-phase trial focused on safety and immune response, not prevention. The vaccine may not produce strong enough immunity to protect against HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV PREVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Contact
-
Emavundleni Clinical Research Site, Desmond Tutu Health Foundation
Cape Town, South Africa
Contact